Home > Oncology > New biomarker for breast-cancer outcomes

New biomarker for breast-cancer outcomes


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Network Open
Reuters Health - 27/11/2020 - Researchers may have found a new biomarker for outcomes of locally advanced breast cancer treated with neoadjuvant chemotherapy. In a paper in JAMA Network Open, they report that low expression of endothelial-cell phosphorylated-focal adhesion kinase was associated with chemotherapy sensitivity and improved relapse-free survival after systemic therapy. Focal adhesion kinase (FAK) is upregulated in breast cancer, and some evidence has suggested that endothelial cell (EC) FAK expression levels correlate with the molecular subtype of breast cancer. Dr. Kairbaan Hodivala-Dilke of Barts Cancer Institute, Queen Mary University of London, and colleagues examined whether phosphorylated Y397-FAK expression levels in the endothelium of breast cancer (EC-pY397-FAK) before treatment were associated with outcomes following anthracycline-based combination neoadjuvant chemotherapy in 82 women with locally advanced breast cancer (stage IIA-IIIC)...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on